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Abstract
Background: The extracellular environment plays an important role in supporting the regeneration of axons after
injury. Metallothionein-II (MTII) is a metal-binding protein known for its neuroprotective effect by directly stimulating
the growth of axons after injury. Previous studies have shown that MTII also modulates the response of astrocytes and
microglia after injury. However, a detailed analysis describing how MTII modulates the interaction between microglia
and neurons is lacking.
Methods: We introduced fluorescently labelled MTII into the cortex at the time of needlestick injury to investigate the
cellular uptake of MTII using immunohistochemistry with antibodies against cell-type-specific markers. The role of MTII
in modulating the effect of microglia on axon outgrowth following an inflammatory response is further investigated
using a co-culture model involving primary rodent microglia pre-treated with TNFα and primary rodent cortical neurons.
The axon lengths were assessed 24 h after the plating of the neurons onto treated microglia. We also utilised siRNA to
knockdown the expression of LRP1, which allows us to investigate the role of LRP1 receptors in the MTII-mediated effect
of microglia on axon outgrowth.
Results: Fluorescently labelled MTII was found to be associated with neurons, astrocytes and microglia following injury
in vivo. Microglia-neuron co-culture experiments demonstrated that exogenous MTII altered the response of microglia
to TNFα. The neurons plated onto the TNFα-stimulated microglia pre-treated with MTII have shown a significantly longer
axonal length compare to the TNFα-stimulated microglia without the MTII treatment. This suggested that MTII reduce
cytokine-stimulated activation of microglia, which would ordinarily impair neurite outgrowth. This inhibitory effect of MTII
on activated microglia was blocked by siRNA-mediated downregulation of LRP1 receptor expression in microglia, suggesting
that MTII acts via the LRP1 receptor on microglia.
Conclusions: This study demonstrates that exogenous MTII acts via the LRP1 receptor to alter the inflammatory response of
microglia following TNFα stimulation, providing a more supportive environment for axon growth.
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Background
Glial cells play an important role in maintaining the health
of neurons and particularly following injury to the central
nervous system (CNS). In this regard, astrocytes and micro-
glia contribute actively to the formation of the glial scar,
which is strongly inhibitory to axon regeneration [1, 2].
Chondroitin sulphate proteoglycans (CSPGs) are one of the
major molecules expressed by glia that contribute to the in-
hibitory environment formed by the glial scar. Modulating
this inhibitory environment using agents such as chondroi-
tinase ABC has been shown to improve the regeneration
outcome after injury [3]. Chondroitinase ABC enzymati-
cally digests CSPG, which improves neuron survival,
axonal growth as well as synaptic plasticity following mid-
dle cerebral artery occlusion [4]. These, and many other
studies [5–7], demonstrate that improving the extracellu-
lar environment plays a vital role in improving axon
regeneration after injury. Apart from CSPG, myelin-
associated inhibitors such as myelin-associated glycopro-
tein (MAG), Nogo and Oligodendrocyte myelin glycopro-
tein (OMgp) are also present in the glial environment and
have a significant role in inhibiting axon outgrowth as well
as plasticity [6, 8, 9, 10]. Soluble inhibitory cues such as
semaphorins are also recognised as having an important
contribution to the inhibitory environment after CNS
injury [9, 10]. In contrast to factors that inhibit neurite
outgrowth, other factors have been identified to promote
neurite outgrowth. These include neurotrophic factors
(such as nerve growth factors, brain-derived neurotrophic
factor) as well as several extracellular matrix attractive guid-
ance molecules that are present at the injury site [6, 9, 10].
The balance between the inhibitory and promoting factors
in the injury site are important in determining the outcome
of axon regeneration after injury.
Metallothionein I/II represents an unusual family of
metal-binding proteins; both MTI and MTII isoform
share a very similar structure as well as have a range of
neurotrophic properties. Our group has previously dem-
onstrated that extracellular MTII directly interacts with
axons and improves axon outgrowth via the low-density
lipoprotein receptor 2 (LRP2, also called megalin) [9, 10].
Apart from its direct actions on neurons, we have also
identified a potential role of MTI/II in modulating the
trophic environment provided by the glial response to
promote neuron regeneration [11, 12]. The use of trans-
genic animals (both MTI/II knockout and MTI overex-
pression mice) has further demonstrated that MTI/II has
an active role in modulating the microglial response after
injury. When a freeze-lesion cortical injury (a localised
cortical injury caused by applying dry ice directly on the
skull) was performed on the mice with MTI overexpres-
sion, this results in a significant decrease in the number of
activated microglia near the freeze lesion site in compari-
son to the wild-type control mice [13]. In contrast, the
freeze-lesion cortical injury in MTI/II-knockout mice
results in an increase in microglia/macrophage infiltration
and activation as well as a delayed in wound repair
process when compared to the wild-type control mice
[14]. Similar results have also been reported in rodent nee-
dlestick injury model, where the administration of extra-
cellular MTII into the injury site improved regenerative
sprouting of axons [15].
Together, these studies suggested that both MTI and
MTII have an active role in modulating the inflammatory
response as well as wound healing after injury. Mechanistic
studies performed in our laboratory have now begun to re-
veal how MTII modulates the neuroinflammatory response
of microglia following traumatic brain injury. We have pre-
viously shown that MTII has a direct effect in decreasing
the expression of quinolinic acid (QUIN) in microglia along
the injury tract in the rat cortical needlestick injury model
[12]. QUIN is one of the neurotoxic intermediates of the
kynurenine pathway that is significantly upregulated in
inflammatory microglia and macrophages [16]. In cultured
microglia, MTII treatment led to a decrease in QUIN
expression upon stimulation with the pro-inflammatory
interferon-γ (IFN-γ) [12]. In the current study, we have
explored the mechanism of MTII signalling in microglia
and the subsequent impact upon neuronal regeneration.
We show that MT modulates the inflammatory response of
tumor necrosis factor (TNF)-α-treated microglia via the
LRP1 receptor and that this action of MTII upon microglia
causes them to become a more permissive substrate to sup-
port axonal outgrowth in vitro.
Methods
MetallothioneinII protein labelling
The MTII protein used in these studies was native rabbit
Zn7-MT-IIA (the major brain-expressed mammalian
MTII isoform) purified by high-performance liquid chro-
matography (Bestenbalt LLC, Estonia). The MTII was
N-terminally tagged using the AlexaFluor® 488 Protein
Labelling Kit (Invitrogen) in accordance with the accom-
panying protocols. During the column fractionation of
labelled protein, all of the eluted fractions were collected
including the unincorporated dye (the second eluted
fluorescent peak). The fractions collected from the first
eluted fluorescent peak contained the MTII conjugated
with the AlexaFluor 488 tag and is hereafter referred to
as MT488, while the unincorporated dye peak was used
as the vehicle treatment and is referred to as A488.
Focal cortical needlestick injury in adult rats
Focal needlestick injuries to the Par1 somatosensory
region of the cortex were performed as described previ-
ously [15]. Briefly, a 1 μL 25-gauge Hamilton syringe was
used to stereotactically deliver the different treatments:
MT488 (2 mg/mL) and A488 into the cortex (n = 4 per
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treatment). The volume of injection for all treatments was
1 μL. The injury was induced by inserting the Hamilton
syringe to a depth of 1.5 mm into the cortex. After leaving
the syringe in place for 5 min, 0.5 μL of the treatment was
injected into the injury site. After a further 5 min, the nee-
dle was first raised by 0.5 mm and the remaining 0.5 μL of
the treatment was then injected into the cortex. Absorb-
ent Gelfoam (soaked with 5 μL of the treatment solution,
either MT488 or A488) was placed on the surface of the
cortex, and the site of injury was sutured closed.
Perfusion and processing of the brain injury site
The animals were sacrificed 4 days after injury by an
intraperitoneal injection of pentobarbitone (0.4 mg/g of
animal weight) to induce a deep anaesthesia followed by
cardiac perfusion with 4% paraformaldehyde. The brain
was then excised and post-fixed in 4% paraformaldehyde
+ 4% sucrose solution in phosphate buffer saline (PBS)
for 24 h. Brains were cryoprotected in 10 and 30%
sucrose solutions (24 h incubation at 4 °C for each solu-
tion) prior to cryosectioning. The brain samples were
cryosectioned at 16 μm in a horizontally sectioned plane
cut parallel to the superior surface of the brain using the
Leica CM1850 Cryostat, and serial sections were then
mounted on APTS-treated microscopic slides. For a con-
sistent comparison between treatments, the sections were
obtained at similar depth across all treatments. Sections
that were collected and processed for immunohistochemis-
try labelling were located from approximately 60 to 540 μm
from the top of the cortex, corresponding to layer II and III
of the supragranular layer of the somatosensory cortex.
Immunohistochemistry on tissue sections
Brain sections were incubated with the following pri-
mary antibodies: Mouse (ms)-SMI312 (1:1000, Covance),
ms-MT (1:1000, Dako), Rabbit (rb)-Iba-1 (1:500, Wako),
Rb- Glial fibrillary acidic protein (GFAP, 1:1000, Dako).
All primary antibodies used were diluted in 0.03%
Triton-X/PBS and incubated at 4 °C overnight. Follow-
ing the incubation, the primary antibodies were washed
three times with PBS. The sections were then incubated
with the respective secondary antibodies: AlexaFluor-
594 or -488 anti-mouse (1:1000, Invitrogen), AlexaFluor-
594 or -488 anti-rabbit (1:1000, Invitrogen). The second-
ary antibodies were diluted in PBS and applied to sec-
tions for 1 h at room temperature prior to incubation
with Nuclear Yellow (1 μg/mL, Molecular Probes) for
5 min. The sections were mounted using fluorescent
mounting agent (Dako).
Image acquisition
Images were captured using either an epifluorescence
microscope (Olympus BX50) with mounted camera (Cool-
SNAP HQ2 camera) or confocal microscope (Zeiss LSM
510). In some cases, a confocal Z-axis series of digital
images was captured through the injury site (minimum
0.5 μm Z-axis spacing).
Purified rodent microglia cultures
Purified rodent microglia cultures were prepared as
described previously [12]. Briefly, mixed glial cultures were
prepared from the cortex of Sprague Dawley postnatal day
2 rat pups in 75 cm2 tissue culture flasks, and maintained
at 37 °C with 5% CO2. The culture medium (Dulbecco’s
modified eagle medium, DMEM, from Sigma + 10% Fetal
calf serum from Gibco + 1% penicillin-streptomycin-
amphotericin B solution from Gibco) was replaced on the
following day with fresh medium, and culture was main-
tained to confluence (around 2 weeks after initial plating).
Upon confluence, the culture medium was changed to
serum-free medium (DMEM + 1% penicillin-streptomycin-
amphotericin B solution), and flasks were horizontally
shaken at 250 rpm for 30 min, which was sufficient to dis-
lodge the microglia in these mixed glial cultures. The cul-
ture medium containing the microglia was collected, and
microglia were pelleted by centrifugation at 500×g for
10 min. Microglia were re-suspended and then plated at
the required number into 24-well plates (15,000 cells per
well containing coverslips pre-coated with 0.025% poly-L-
lysine). Microglia were maintained in serum-free media
until confluence.
Neuron and microglia co-culture
Microglia were collected and plated onto glass coverslips
in serum-free media as described previously. Two days
after the plating of microglia, the cultures were incu-
bated with the respective treatment accordingly for 24 h
in serum-free media. These treatments were 10 ng/mL
TNFα (Abcam) with or without MTII (1 μg/mL) and
saline (vehicle treatment). Cortical neuron cultures were
prepared as reported previously from embryonic day 17
Sprague-Dawley rats [15]. In order to prevent the effect
of the extracellular MTII or TNFα on the growing
neurons, the media of the microglia culture was changed
to neuron media (Neurobasal™ medium supplement with
B-27 supplement, 0.1 mM L-glutamine and 10% fetal
bovine serum from Gibco) prior to the addition of
cortical neurons on top of the microglia at cell density
of 2 × 104 cells per well. Co-cultures were incubated for
24 h followed by fixation with 4% paraformaldehyde for
15 min at room temperature.
siRNA knockdown of LRP1 receptors
We then employed pre-designed siRNA (ThermoFisher
Scientific) to selectively knockdown the LRP1 receptors
in microglia cultures as described previously [17]. The
knockdown of LRP1 receptors expression in microglia
was also confirmed via Western blotting as described
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previously [17]. The microglia were first collected (as
above) and resuspended in 1 mL of serum-free media con-
taining 100 nM of siRNA against LRP1 (from Thermo-
Fisher Scientific). The microglia were plated into 24-well
plates (procedure stated as above) and incubated for 1 h at
37 °C 5% CO2. The concentration of the siRNA was
diluted down to 10 nM in the well by adding in the add-
itional culture media; the cultures were then returned
back to the incubator.
Immunocytochemistry on culture
Fixed cultures were incubated with primary antibodies
(ms-SMI312 used at 1:1000, Covance; rb-LRP1 used at
1:1000, Sigma-Aldrich; rb-megalin used at 1:1000, Santa
Cruz Biotechnology) diluted in 0.03% Triton-X/PBS for
24 h at 4 °C. The primary antibodies were then washed
three times in PBS (5 min per washes on shaker at room
temperature). The coverslips were incubated with sec-
ondary antibodies (AlexaFluor-488 anti-mouse used at
1:1000, Invitrogen) in PBS for 1 h at room temperature
on a shaker. All cultures were labelled with Nuclear Yel-
low (1 μg/mL, 5 min) followed by two times washes with
PBS. Cultures were mounted on glass slides using fluor-
escent mounting agent (Dako).
Imaging and statistical analysis
Digital images (five images per coverslips) of SMI312
immunolabelled axons were acquired on a fluorescence
microscope (Leica DM-LB2) with an Olympus Magnifier
cooled-CCD camera. Lengths of axons were measured
using ImageJ (National Institute of Health) software. The
data were analysed using the Student t test, with p < 0.05
considered as significant. For MTII and TNFα experi-
ment, n = 4 experimental cultures were prepared and one
coverslip per culture per treatment group was used. For
LRP1 siRNA experiment, n = 4 experimental cultures were
prepared and two coverslips per culture per treatment
group were used.
Results
Exogenous metallothionein-II is associated with neuron,
astrocytes and microglia after needlestick injury
Our previous studies have shown that MTII can promote
neurite outgrowth of cultured cortical neurons [15], through
a mechanism involving LRP receptors and downstream
MAPK signalling [9, 10]. We have also shown in cell culture
that MTII can modulate the astrocytic response to neuro-
trauma, leading to a more permissive environment to allow
the extension of axons [11]. Similarly, MTII can act upon
cultured microglia to suppress their inflammatory activation
following cytokine stimulation. When administered by direct
injection into the site of a cortical needlestick injury, MTII
modulates glial reactivity and promotes regenerative axonal
sprouting [15]. What remains unclear is which cell type/s
are directly modulated by MTII treatment in vivo and the
sequence of cellular events elicited by MTII that ultimately
contributes to improved neural regeneration. To investigate
this, we utilised fluorescently labelled MTII (MT488), which
was introduced into the cortex via the needlestick injury.
Tissue was harvested at 4 days post-injury prior to
immunohistochemistry.
We first confirmed that the administration of MT488 pro-
duces the same neuroprotective effect that has been
reported previously. Accordingly, it was found that MT488
reduced the severity of the experimental injury, clearly
observable by immunohistochemistry of axonal structures
(using antibody against SMI312) (results not shown). This
demonstrates that the MT488 displays similar neurotrophic
activity to unlabelled MTII [15].
We characterised the cells that are associated with the
administered MT488 after injury by performing immuno-
fluorescent labelling using markers for neurons (SMI312,
phosphorylated neurofilament), astrocytes (GFAP) and
microglia (Iba-1) (Fig. 1). We show that MT488 was associ-
ated with neurons (particularly prevalent in axonal struc-
tures labelled with SMI312; Fig. 1a), microglia and
astrocytes (labelled with Iba-1 and GFAP; Fig. 1d, g). In
control tissue injected with A488, none of the neurons and
astrocytes was associated with the injected A488; however,
the A488 was shown to be associated with the Iba-1 posi-
tive microglia (Fig. 1g). Notably, microglia that had associ-
ated with MT488 displayed a ramified morphology, while
those associating with A488 displayed a rounded (or
amoeboid) morphology. We also observed that the major-
ity of the MT488 was located within cellular structures
surrounding the lesion site. In contrast, A488 was mainly
located within the lesion site along with the cells debris.
Role of metallothionein-II in modifying microglial
response after injury
Given that the uptake of MT488 was observed within
microglia and that this was associated with an altered cellu-
lar morphology, we next examined the effect of exogenous
MTII upon reactive microglia, using an in vitro microglia
and neuron co-culture model. Firstly, we established the ef-
fect of activated microglia (TNFα stimulated) upon neurite
outgrowth of co-cultured cortical neurons. Measurement of
axonal extension 24 h after the plating of cortical neurons
demonstrated that axons grown on activated microglia
(TNFα-treated) were significantly (p < 0.05) shorter than
axons grown on microglia treated with saline (vehicle)
(Fig. 2a, b). When the axons were plated on microglia that
were pre-treated with TNFα and MTII (Fig. 2c), the length
of the axons was significantly longer than neurons treated
with TNFα only and not significantly different to the saline-
treated microglia (Fig. 2d). This demonstrated that the
addition of MTII on TNFα-treated microglia ameliorated
the inhibitory activity of TNFα-treated microglia, restoring
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neurite outgrowth to a level similar to that in cells receiving
the vehicle treatment (Fig. 2).
Metallothionein-II acts through LRP1 receptors in
microglia
We have previously demonstrated that MTII acts through
the LRP2 (or megalin) receptor on neurons to improve
regenerative sprouting of injured neurons [9, 10]. Here,
we determined if LRP receptors are also involved in the
action of MTII upon cultured microglia. We firstly char-
acterised the LRP expression in cultured microglia, and
we observed a robust immunolabelling of LRP1 primarily
present in the cell bodies (Fig. 3a). In contrast, no LRP2
labelling was observed in the cultured microglia (Fig. 3b).
Fig. 1 Fluorescently labelled Metallothionein I/II (MT488) is taken up by neurons, astrocytes and microglia after needlestick injury. Immunohistochemistry
using markers to label the neurons (SMI312), astrocytes (GFAP) and microglia (Iba-1) on frozen cortical sections collected from adult rat 4 days after
receiving needlestick injury with either the A488 or MT488. The MT488, but not A488, was visible in neurons (a); higher magnification images shown in b and
c, similarly, the astrocytes also appeared to take up the MT488 but not A488 (d); higher magnification images shown in e and f. In contrast, both A488 and
MT488 were taken up by microglia (g); higher magnification images shown in h and i. The microglia that taken up A488 appear in a more amoeboid-like
morphology when compared to the microglia receiving the MT488, which had a more ramified phenotype. (Scale bar in a, d and g = 50 μm; b, c, e, g, h
and i = 12 μm)
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To determine whether LRP1 is involved in the action
of MTII upon cultured microglia, we employed siRNA
against LRP1 in the microglia-neuron co-culture model.
We first validated the selectivity of the siRNA against
LRP 1 receptors in our previous publication [17]. The
decreased expression of LRP1 receptors in the presence
of siRNA was also confirmed using Western blot
(Fig. 3c). We then examined the effect of knocking down
LRP1 expression upon the ability of MTII to modulate
inflammatory-activated microglia to promote neurite
outgrowth. We found that the effect of MTII upon
TNFα-stimulated microglia was ablated with reduced
LRP1 expression, suggesting that MTII exerts its effect
through the LRP1 receptor in vitro (Fig. 3d).
Discussion
In this study, we first demonstrated that the majority of
the exogenously administered MT488 and A488 associated
with the Iba1-labelled microglia/macrophages within close
proximity to the needlestick injury in the cortex. The asso-
ciation of both the MT488 and A488 may be in accordance
with the well-described function of microglia to phagocyt-
ose foreign material [18]. Using this fluorescence-labelled
protein model, we can only demonstrate the association of
MTII to microglia in vivo. A further study that involves
injecting unlabelled MTII into a transgenic MT-null mice
model will be needed to confirm the fate of the injected
MTII via post-mortem immunolabelling. However, from
what we observed using the fluorescence-labelled MTII,
the microglia that had associated with MT488 had a rami-
fied phenotype in comparison to those internalising A488.
Previous studies have suggested the presence of two sub-
types of microglia in the CNS; however, recent studies
have suggested that these two subtypes could potentially
be extremes of a spectrum between the neuro-toxic (M1)
to neuro-protective roles (M2) that microglia have in
response to an extracellular signal [19]. The changes in
microglia phenotype in the presence of MTII observed in
this study indicate that MTII plays a role in altering the
function of the microglia to a more neuro-protective form
rather than a switch in the subtypes. However, further
study is needed to clarify the expression of the neuro-
protective phenotype markers in the microglia of the
brains treated with MT488. It should be noted in this
experiment model, the amount of MTII injected (1 μL of
2 mg/mL of MTII) is not a significant amount compared
to the endogenous MTII concentration in human. The
concentration of the MTII used in this experiment model
is mainly to allow us to study the cellular association of
extracellular MTII, which is the main aim of this experi-
ment. A limitation of this study is the use of the Iba-1
antibody, which labelled both microglia and infiltrating
peripheral macrophages; this makes it difficult to specify
whether the cells that have internalised the A488 and
MT488 are microglia or infiltrated macrophages or both.
To further investigate the direct influence that MTII has
on microglia, we utilised a microglia-neuron co-culture
model. In this co-culture model, the microglia is pre-
conditioned with either TNFα only or TNFα and MTII in
serum-free media, which is then replaced with neurobasal
media containing 10% serum prior to the plating of cor-
tical neurons; therefore, the addition of the serum-derived
MTII will not affect the pre-conditioning on microglia
from the treatments, hence the experiment outcome from
the co-culture model. Using this model, we have demon-
strated that pre-treating the microglia with TNFα (a pro-
inflammatory cytokine) led to a decrease in neurite
outgrowth and that the addition of MTII abrogated this
effect. Hence, this demonstrated that MTII is capable of
exerting a specific effect upon TNFα-treated microglia in
culture. It has been recently demonstrated that TNFα
treatment in primary microglia culture leads to an inflam-
matory response via suppressing the expression LRP1
[20]. The activation of LRP1 receptors has been shown in
various studies to be involved in decreasing the inflamma-
tory response of microglia. It has also been demonstrated
that MTII bind to both LRP1 and LRP2 (also known as
megalin) receptors in neurons [9, 10, 21]. In this study, we
hypothesised that MTII bind to LRP1 receptor on microglia
Fig. 2 Microglial inflammatory response was inhibitory to axonal
outgrowth and this could be modulated (or improved) by extracellular
metallothionein-II (MT). a shows the immunohistochemistry of neurons
in the co-culture using the SMI312 antibody. The neurons treated with
TNFα has a shorter process (or axon) when compare to vehicle. The
addition of MT to the TNFα treatment has restored this inhibitory effect
to a similar level as that receiving vehicle treatment (a–c). d shows the
quantitative measurement of the neurite length relative to the vehicle
treatment. (Scale Bar in a = 12 μm) (*p < 0.05 compared to vehicle
treatment and TNFα + MT using ANOVA; n = 4 experimental cultures
per treatment group; error bars = standard errors of the mean fold
difference relative to vehicle treatment)
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which leads to a decrease in the inflammatory response in
microglia through its action on LRP1 receptors. To investi-
gate this, we have utilised siRNA to knockdown LRP1
receptors in our microglia and neuron co-cultures. Our
results demonstrated that the knockdown of LRP1 receptor
attenuates the effect of MTII in promoting neurite out-
growth after TNFα treatment. This suggests that MTII
modulates microglia function via the LRP1 receptor.
This is the first report showing that MTII acts through
the LRP1 receptor to alter the microglia response. It has
been previously reported that LRP1 receptor activation by
an Apolipoprotein-E (Apo-E) mimetic peptide also
decreases the microglia inflammatory response via a
mitogen-activated protein kinase (MAPK) dependent path-
way [22]. Notably, we have reported previously that MTII
stimulates the growth of cultured cortical neurons via LRP2
or the megalin receptor [9, 10]. Collectively, this suggests
that LRP signalling could be involved in promoting axon
regeneration and neural recovery following traumatic injury
via multiple cellular pathways. We have previously reported
that MTII modulates the behaviour of reactive astrocytes
through a JAK/STAT signalling pathway [11]. A recent
study had also demonstrated the involvement of LRP1 in
microglia activation via modulating the JNK and NF-
Fig. 3 Metallothionein II (MT) alter the TNFα-treated microglia response via LRP1 receptors in microglia and neuron co-culture model. Immunohistochemistry
labelling using antibodies against LRP1 and LRP2 demonstrated that cultured microglia express LRP1 but not LRP2 receptors (a and b). c shows the Western
blot performed on the protein extracted from microglia culture receiving 10 nM siRNA or no siRNA. In comparison to the no siRNA control, there is a decrease
in the expression of LRP1 (both 100kD and 70kD band). The brain extract from rat cortex was also used as an internal positive control for this western blot. d
shows the quantitative results from the microglia-neuron co-culture with the treatment of siRNA against LRP1 added to the microglia in conjunction with the
treatments (TNFα or TNFα + MT). Similar to the result shown previously, in cultures not receiving the siRNA, the neurite length was higher in the microglia
pre-treated with MT and TNFα when compare to the treatment with TNFα. The addition of siRNA against LRP1 in the TNFα-treated microglia did not led
to significant changes in the neurite length when compared to the TNFα treatment without the siRNA. In contrast, the addition of siRNA against LRP1
did not significantly increase the neurite length. (Scale bar at Figure A = 25 μm) (*p < 0.05 compared to other treatment; n = 4 experimental cultures
per treatment group, ANOVA; error bars = standard errors of the mean neurite length)
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kappaB signalling pathways [20]. The JAK/STAT, JNK and
NF-kappaB have been demonstrated to be important stress
kinase pathways involved in microglia inflammatory response
[23]. Thus, these pathways could potentially be the down-
stream pathway for MTII-LRP1 interaction in microglia;
however, this will need to be confirmed in future studies.
In this current study, MTII treatment caused a distinct
change in the morphology of microglia. In saline-treated
animals, microglia displayed a spherical and amoeboid
morphology that is proposed to be associated with a react-
ive and inflammatory phenotype that inhibits neural re-
generation (commonly referred to as the M1 phenotype)
[24]. However, MTII treatment caused a clear difference
in microglial morphology, resulting in ramified structures
that resemble the M2 phenotype that supports neural
regeneration [24]. Our in vitro studies support the obser-
vation that MTII induces a pro-regenerative microglial
phenotype in response to TNFα. Collectively, our data
clearly demonstrates that MTII activates an LRP1
receptor-dependent pathway in microglia, providing for
the first time a mechanistic explanation for the numerous
in vivo reports that MTII modulates the microglial
response to CNS injury and stress [12–14, 16].
Conclusions
In conclusion, this study has presented data supporting
the neuroprotective role of MTII via modulating the
microglia inflammatory response. This study has also
identified LRP1 as a receptor for MTII in microglia, which
further demonstrates the importance of LRP1 receptors in
modulating the microglial response to promote axonal
growth after injury. This study has demonstrated that in
addition to the direct role that MTII exerts on neurons to
promote their regeneration, MTII also indirectly promotes
the regeneration (or recovery) of the damaged neurons by
improving the extracellular environment (glial response)
to support the axon regeneration after injury.
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